Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695-8204, USA.
AAPS J. 2010 Mar;12(1):51-60. doi: 10.1208/s12248-009-9159-3. Epub 2009 Nov 25.
Recently, the RNA interference (RNAi) pathway has become the target of small molecule inhibitors and activators. RNAi has been well established as a research tool in the sequence-specific silencing of genes in eukaryotic cells and organisms by using exogenous, small, double-stranded RNA molecules of approximately 20 nucleotides. Moreover, a recently discovered post-transcriptional gene regulatory mechanism employs microRNAs (miRNAs), a class of endogenously expressed small RNA molecules, which are processed via the RNAi pathway. The chemical modulation of RNAi has important therapeutic relevance, because a wide range of miRNAs has been linked to a variety of human diseases, especially cancer. Thus, the activation of tumor-suppressive miRNAs and the inhibition of oncogenic miRNAs by small molecules have the potential to provide a fundamentally new approach for the development of cancer therapeutics.
最近,RNA 干扰 (RNAi) 途径已成为小分子抑制剂和激活剂的靶标。RNAi 已被很好地确立为一种研究工具,可通过使用约 20 个核苷酸的外源、小、双链 RNA 分子在真核细胞和生物体中对基因进行序列特异性沉默。此外,最近发现的一种转录后基因调控机制利用了 microRNAs(miRNAs),一类内源性表达的小 RNA 分子,它们通过 RNAi 途径进行加工。RNAi 的化学调节具有重要的治疗相关性,因为广泛的 miRNAs 与多种人类疾病,特别是癌症有关。因此,通过小分子激活肿瘤抑制性 miRNAs 并抑制致癌性 miRNAs,有可能为癌症治疗药物的开发提供一种全新的方法。